Latest News and Press Releases
Want to stay updated on the latest news?
-
ROCKVILLE, Md., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine...
-
ROCKVILLE, Md., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the quarter ended September 25, 2010. The Company...
-
ROCKVILLE, Md., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) will report its third quarter 2010 financial results on Wednesday, November 3, 2010, after the market close. The...
-
ROCKVILLE, Md., Sept. 7, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that Dr. Raafat Fahim, President and Chief Executive Officer, will present at the Rodman &...
-
ROCKVILLE, Md., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc....
-
ROCKVILLE, Md., Aug. 24, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX® and related...
-
ROCKVILLE, Md., Aug. 10, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it has successfully completed the technology transfer of program know-how associated with...
-
ROCKVILLE, Md., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its second quarter financial results for the three month period ended June 26, 2010. The Company...
-
ROCKVILLE, Md., July 26, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) will report its second quarter 2010 financial results on Thursday, August 5, 2010, after the market close. The...
-
ROCKVILLE, Md., July 14, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it has completed enrollment in the first Phase III clinical trial of NicVAX® (Nicotine...